Loading…

Psychoeducation Improves Hepatitis C Virus Treatment During Opioid Substitution Therapy: A Controlled, Prospective Multicenter Trial

Background. People who inject drugs (PWID) have a high prevalence of hepatitis C virus (HCV) infection. However, PWID are considered “difficult to treat,” requiring a specifically adapted treatment setting, including psychosocial support. Methods. In this prospective, German trial, the impact of psy...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2013-08, Vol.57 (suppl_2), p.S97-S104
Main Authors: Reimer, Jens, Schmidt, Christiane Sybille, Schulte, Bernd, Gansefort, Dirk, Gölz, Jörg, Gerken, Guido, Scherbaum, Norbert, Verthein, Uwe, Backmund, Markus
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c373t-7ad8e02a5f6c72f8dd63156cfaa08606b14031ad95da1a3474e19c362e3611853
cites cdi_FETCH-LOGICAL-c373t-7ad8e02a5f6c72f8dd63156cfaa08606b14031ad95da1a3474e19c362e3611853
container_end_page S104
container_issue suppl_2
container_start_page S97
container_title Clinical infectious diseases
container_volume 57
creator Reimer, Jens
Schmidt, Christiane Sybille
Schulte, Bernd
Gansefort, Dirk
Gölz, Jörg
Gerken, Guido
Scherbaum, Norbert
Verthein, Uwe
Backmund, Markus
description Background. People who inject drugs (PWID) have a high prevalence of hepatitis C virus (HCV) infection. However, PWID are considered “difficult to treat,” requiring a specifically adapted treatment setting, including psychosocial support. Methods. In this prospective, German trial, the impact of psychoeducation (PE) on retention and sustained virologic response (SVR) during HCV therapy among PWID was evaluated. We included 198 patients in opiate substitution therapy, who fulfilled indications for antiviral treatment. All patients received pegylated interferon alfa-2a and ribavirin therapy. Patients in the intervention group (n = 82) received manualized PE sessions. Results. In patients with HCV genotype 1 or 4 (GT 1/4), PE was associated with increased treatment completion (76% vs 55%, P = .038), whereas PE had no such effect among GT 2/3 patients, who showed fewer dropouts and higher SVR rates. Among GT 1/4 patients, a minimum of 5 PE sessions was associated with increased SVR (71% vs 48%, P = .037). Multivariate regression analyses confirmed the impact of PE in GT 1/4 and revealed further predictors for retention and SVR, such as preexisting mental distress and adverse events. Conclusions. In patients with a higher risk of dropout due to GT 1/4 or mental distress, PE was shown to improve retention and SVR. PE is an effective supportive intervention for intervention for HCV therapy among PWID. Clinical Trials Registration. NCT00844272.
doi_str_mv 10.1093/cid/cit307
format article
fullrecord <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1417528725</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>23484004</jstor_id><sourcerecordid>23484004</sourcerecordid><originalsourceid>FETCH-LOGICAL-c373t-7ad8e02a5f6c72f8dd63156cfaa08606b14031ad95da1a3474e19c362e3611853</originalsourceid><addsrcrecordid>eNpdkc1rFTEUxUOptLW6cW8JuBFxNJl8Pnfl-dFCSwu-uh3ykjs2j5nJmI_C2_uHm_pakS4uueT8csjhIPSKkg-ULNhH612dzIjaQ0dUMNVIsaD7dSdCN1wzfYiep7QhhFJNxAE6bJnWnCh2hH5fp629DeCKNdmHCZ-Pcwx3kPAZzPUm-4SX-IePJeFVBJNHmDL-XKKffuKr2Qfv8PeyTpUsf9-vbiGaefsJn-JlmHIMwwDuPb6OIc1gs78DfFmG7G31gVg9vRleoGe9GRK8fDiP0c3XL6vlWXNx9e18eXrRWKZYbpRxGkhrRC-tanvtnGRUSNsbQ7Qkck05YdS4hXCGGsYVB7qwTLbAZE0u2DF6u_OtEX8VSLkbfbIwDGaCUFJHOVWi1aq9R988QTehxKn-rqOCS0G0ULJS73aUrfFShL6box9N3HaUdPfddLWbbtdNhU8eLMt6BPcPfSyjAq93wCblEP_TedUJZ38ANEWVuA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1546508576</pqid></control><display><type>article</type><title>Psychoeducation Improves Hepatitis C Virus Treatment During Opioid Substitution Therapy: A Controlled, Prospective Multicenter Trial</title><source>JSTOR Archival Journals and Primary Sources Collection</source><source>Oxford Journals Online</source><creator>Reimer, Jens ; Schmidt, Christiane Sybille ; Schulte, Bernd ; Gansefort, Dirk ; Gölz, Jörg ; Gerken, Guido ; Scherbaum, Norbert ; Verthein, Uwe ; Backmund, Markus</creator><creatorcontrib>Reimer, Jens ; Schmidt, Christiane Sybille ; Schulte, Bernd ; Gansefort, Dirk ; Gölz, Jörg ; Gerken, Guido ; Scherbaum, Norbert ; Verthein, Uwe ; Backmund, Markus</creatorcontrib><description>Background. People who inject drugs (PWID) have a high prevalence of hepatitis C virus (HCV) infection. However, PWID are considered “difficult to treat,” requiring a specifically adapted treatment setting, including psychosocial support. Methods. In this prospective, German trial, the impact of psychoeducation (PE) on retention and sustained virologic response (SVR) during HCV therapy among PWID was evaluated. We included 198 patients in opiate substitution therapy, who fulfilled indications for antiviral treatment. All patients received pegylated interferon alfa-2a and ribavirin therapy. Patients in the intervention group (n = 82) received manualized PE sessions. Results. In patients with HCV genotype 1 or 4 (GT 1/4), PE was associated with increased treatment completion (76% vs 55%, P = .038), whereas PE had no such effect among GT 2/3 patients, who showed fewer dropouts and higher SVR rates. Among GT 1/4 patients, a minimum of 5 PE sessions was associated with increased SVR (71% vs 48%, P = .037). Multivariate regression analyses confirmed the impact of PE in GT 1/4 and revealed further predictors for retention and SVR, such as preexisting mental distress and adverse events. Conclusions. In patients with a higher risk of dropout due to GT 1/4 or mental distress, PE was shown to improve retention and SVR. PE is an effective supportive intervention for intervention for HCV therapy among PWID. Clinical Trials Registration. NCT00844272.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/cit307</identifier><identifier>PMID: 23884073</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Adolescent ; Adult ; Aged ; Antiviral Agents - administration &amp; dosage ; Antiviral drugs ; Behavior Therapy - methods ; Clinical trials ; Drug therapy ; Female ; Germany ; Hepatitis ; Hepatitis C ; Hepatitis C - drug therapy ; Humans ; Interferon-alpha - administration &amp; dosage ; Male ; Medical treatment ; Medication Adherence ; Middle Aged ; Narcotics ; Opiate Substitution Treatment - methods ; Polyethylene Glycols - administration &amp; dosage ; Prospective Studies ; Recombinant Proteins - administration &amp; dosage ; Ribavirin - administration &amp; dosage ; Substance Abuse, Intravenous - complications ; Substance Abuse, Intravenous - drug therapy ; Treatment Outcome ; Viral Load ; Young Adult</subject><ispartof>Clinical infectious diseases, 2013-08, Vol.57 (suppl_2), p.S97-S104</ispartof><rights>Copyright Oxford University Press, UK Aug 15, 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c373t-7ad8e02a5f6c72f8dd63156cfaa08606b14031ad95da1a3474e19c362e3611853</citedby><cites>FETCH-LOGICAL-c373t-7ad8e02a5f6c72f8dd63156cfaa08606b14031ad95da1a3474e19c362e3611853</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/23484004$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/23484004$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,58238,58471</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23884073$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reimer, Jens</creatorcontrib><creatorcontrib>Schmidt, Christiane Sybille</creatorcontrib><creatorcontrib>Schulte, Bernd</creatorcontrib><creatorcontrib>Gansefort, Dirk</creatorcontrib><creatorcontrib>Gölz, Jörg</creatorcontrib><creatorcontrib>Gerken, Guido</creatorcontrib><creatorcontrib>Scherbaum, Norbert</creatorcontrib><creatorcontrib>Verthein, Uwe</creatorcontrib><creatorcontrib>Backmund, Markus</creatorcontrib><title>Psychoeducation Improves Hepatitis C Virus Treatment During Opioid Substitution Therapy: A Controlled, Prospective Multicenter Trial</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Background. People who inject drugs (PWID) have a high prevalence of hepatitis C virus (HCV) infection. However, PWID are considered “difficult to treat,” requiring a specifically adapted treatment setting, including psychosocial support. Methods. In this prospective, German trial, the impact of psychoeducation (PE) on retention and sustained virologic response (SVR) during HCV therapy among PWID was evaluated. We included 198 patients in opiate substitution therapy, who fulfilled indications for antiviral treatment. All patients received pegylated interferon alfa-2a and ribavirin therapy. Patients in the intervention group (n = 82) received manualized PE sessions. Results. In patients with HCV genotype 1 or 4 (GT 1/4), PE was associated with increased treatment completion (76% vs 55%, P = .038), whereas PE had no such effect among GT 2/3 patients, who showed fewer dropouts and higher SVR rates. Among GT 1/4 patients, a minimum of 5 PE sessions was associated with increased SVR (71% vs 48%, P = .037). Multivariate regression analyses confirmed the impact of PE in GT 1/4 and revealed further predictors for retention and SVR, such as preexisting mental distress and adverse events. Conclusions. In patients with a higher risk of dropout due to GT 1/4 or mental distress, PE was shown to improve retention and SVR. PE is an effective supportive intervention for intervention for HCV therapy among PWID. Clinical Trials Registration. NCT00844272.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antiviral Agents - administration &amp; dosage</subject><subject>Antiviral drugs</subject><subject>Behavior Therapy - methods</subject><subject>Clinical trials</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Germany</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C - drug therapy</subject><subject>Humans</subject><subject>Interferon-alpha - administration &amp; dosage</subject><subject>Male</subject><subject>Medical treatment</subject><subject>Medication Adherence</subject><subject>Middle Aged</subject><subject>Narcotics</subject><subject>Opiate Substitution Treatment - methods</subject><subject>Polyethylene Glycols - administration &amp; dosage</subject><subject>Prospective Studies</subject><subject>Recombinant Proteins - administration &amp; dosage</subject><subject>Ribavirin - administration &amp; dosage</subject><subject>Substance Abuse, Intravenous - complications</subject><subject>Substance Abuse, Intravenous - drug therapy</subject><subject>Treatment Outcome</subject><subject>Viral Load</subject><subject>Young Adult</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNpdkc1rFTEUxUOptLW6cW8JuBFxNJl8Pnfl-dFCSwu-uh3ykjs2j5nJmI_C2_uHm_pakS4uueT8csjhIPSKkg-ULNhH612dzIjaQ0dUMNVIsaD7dSdCN1wzfYiep7QhhFJNxAE6bJnWnCh2hH5fp629DeCKNdmHCZ-Pcwx3kPAZzPUm-4SX-IePJeFVBJNHmDL-XKKffuKr2Qfv8PeyTpUsf9-vbiGaefsJn-JlmHIMwwDuPb6OIc1gs78DfFmG7G31gVg9vRleoGe9GRK8fDiP0c3XL6vlWXNx9e18eXrRWKZYbpRxGkhrRC-tanvtnGRUSNsbQ7Qkck05YdS4hXCGGsYVB7qwTLbAZE0u2DF6u_OtEX8VSLkbfbIwDGaCUFJHOVWi1aq9R988QTehxKn-rqOCS0G0ULJS73aUrfFShL6box9N3HaUdPfddLWbbtdNhU8eLMt6BPcPfSyjAq93wCblEP_TedUJZ38ANEWVuA</recordid><startdate>20130815</startdate><enddate>20130815</enddate><creator>Reimer, Jens</creator><creator>Schmidt, Christiane Sybille</creator><creator>Schulte, Bernd</creator><creator>Gansefort, Dirk</creator><creator>Gölz, Jörg</creator><creator>Gerken, Guido</creator><creator>Scherbaum, Norbert</creator><creator>Verthein, Uwe</creator><creator>Backmund, Markus</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20130815</creationdate><title>Psychoeducation Improves Hepatitis C Virus Treatment During Opioid Substitution Therapy: A Controlled, Prospective Multicenter Trial</title><author>Reimer, Jens ; Schmidt, Christiane Sybille ; Schulte, Bernd ; Gansefort, Dirk ; Gölz, Jörg ; Gerken, Guido ; Scherbaum, Norbert ; Verthein, Uwe ; Backmund, Markus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c373t-7ad8e02a5f6c72f8dd63156cfaa08606b14031ad95da1a3474e19c362e3611853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antiviral Agents - administration &amp; dosage</topic><topic>Antiviral drugs</topic><topic>Behavior Therapy - methods</topic><topic>Clinical trials</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Germany</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C - drug therapy</topic><topic>Humans</topic><topic>Interferon-alpha - administration &amp; dosage</topic><topic>Male</topic><topic>Medical treatment</topic><topic>Medication Adherence</topic><topic>Middle Aged</topic><topic>Narcotics</topic><topic>Opiate Substitution Treatment - methods</topic><topic>Polyethylene Glycols - administration &amp; dosage</topic><topic>Prospective Studies</topic><topic>Recombinant Proteins - administration &amp; dosage</topic><topic>Ribavirin - administration &amp; dosage</topic><topic>Substance Abuse, Intravenous - complications</topic><topic>Substance Abuse, Intravenous - drug therapy</topic><topic>Treatment Outcome</topic><topic>Viral Load</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reimer, Jens</creatorcontrib><creatorcontrib>Schmidt, Christiane Sybille</creatorcontrib><creatorcontrib>Schulte, Bernd</creatorcontrib><creatorcontrib>Gansefort, Dirk</creatorcontrib><creatorcontrib>Gölz, Jörg</creatorcontrib><creatorcontrib>Gerken, Guido</creatorcontrib><creatorcontrib>Scherbaum, Norbert</creatorcontrib><creatorcontrib>Verthein, Uwe</creatorcontrib><creatorcontrib>Backmund, Markus</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reimer, Jens</au><au>Schmidt, Christiane Sybille</au><au>Schulte, Bernd</au><au>Gansefort, Dirk</au><au>Gölz, Jörg</au><au>Gerken, Guido</au><au>Scherbaum, Norbert</au><au>Verthein, Uwe</au><au>Backmund, Markus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Psychoeducation Improves Hepatitis C Virus Treatment During Opioid Substitution Therapy: A Controlled, Prospective Multicenter Trial</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2013-08-15</date><risdate>2013</risdate><volume>57</volume><issue>suppl_2</issue><spage>S97</spage><epage>S104</epage><pages>S97-S104</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Background. People who inject drugs (PWID) have a high prevalence of hepatitis C virus (HCV) infection. However, PWID are considered “difficult to treat,” requiring a specifically adapted treatment setting, including psychosocial support. Methods. In this prospective, German trial, the impact of psychoeducation (PE) on retention and sustained virologic response (SVR) during HCV therapy among PWID was evaluated. We included 198 patients in opiate substitution therapy, who fulfilled indications for antiviral treatment. All patients received pegylated interferon alfa-2a and ribavirin therapy. Patients in the intervention group (n = 82) received manualized PE sessions. Results. In patients with HCV genotype 1 or 4 (GT 1/4), PE was associated with increased treatment completion (76% vs 55%, P = .038), whereas PE had no such effect among GT 2/3 patients, who showed fewer dropouts and higher SVR rates. Among GT 1/4 patients, a minimum of 5 PE sessions was associated with increased SVR (71% vs 48%, P = .037). Multivariate regression analyses confirmed the impact of PE in GT 1/4 and revealed further predictors for retention and SVR, such as preexisting mental distress and adverse events. Conclusions. In patients with a higher risk of dropout due to GT 1/4 or mental distress, PE was shown to improve retention and SVR. PE is an effective supportive intervention for intervention for HCV therapy among PWID. Clinical Trials Registration. NCT00844272.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>23884073</pmid><doi>10.1093/cid/cit307</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1058-4838
ispartof Clinical infectious diseases, 2013-08, Vol.57 (suppl_2), p.S97-S104
issn 1058-4838
1537-6591
language eng
recordid cdi_proquest_miscellaneous_1417528725
source JSTOR Archival Journals and Primary Sources Collection; Oxford Journals Online
subjects Adolescent
Adult
Aged
Antiviral Agents - administration & dosage
Antiviral drugs
Behavior Therapy - methods
Clinical trials
Drug therapy
Female
Germany
Hepatitis
Hepatitis C
Hepatitis C - drug therapy
Humans
Interferon-alpha - administration & dosage
Male
Medical treatment
Medication Adherence
Middle Aged
Narcotics
Opiate Substitution Treatment - methods
Polyethylene Glycols - administration & dosage
Prospective Studies
Recombinant Proteins - administration & dosage
Ribavirin - administration & dosage
Substance Abuse, Intravenous - complications
Substance Abuse, Intravenous - drug therapy
Treatment Outcome
Viral Load
Young Adult
title Psychoeducation Improves Hepatitis C Virus Treatment During Opioid Substitution Therapy: A Controlled, Prospective Multicenter Trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T03%3A47%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Psychoeducation%20Improves%20Hepatitis%20C%20Virus%20Treatment%20During%20Opioid%20Substitution%20Therapy:%20A%20Controlled,%20Prospective%20Multicenter%20Trial&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Reimer,%20Jens&rft.date=2013-08-15&rft.volume=57&rft.issue=suppl_2&rft.spage=S97&rft.epage=S104&rft.pages=S97-S104&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/cit307&rft_dat=%3Cjstor_proqu%3E23484004%3C/jstor_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c373t-7ad8e02a5f6c72f8dd63156cfaa08606b14031ad95da1a3474e19c362e3611853%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1546508576&rft_id=info:pmid/23884073&rft_jstor_id=23484004&rfr_iscdi=true